AR114735A1 - METHOD FOR ULTRA-RAPID AFFINITY SCREENING OF MHC-PEPTIDE COMPLEXES IN SEARCH OF TCR LIGANDS - Google Patents
METHOD FOR ULTRA-RAPID AFFINITY SCREENING OF MHC-PEPTIDE COMPLEXES IN SEARCH OF TCR LIGANDSInfo
- Publication number
- AR114735A1 AR114735A1 ARP190102633A ARP190102633A AR114735A1 AR 114735 A1 AR114735 A1 AR 114735A1 AR P190102633 A ARP190102633 A AR P190102633A AR P190102633 A ARP190102633 A AR P190102633A AR 114735 A1 AR114735 A1 AR 114735A1
- Authority
- AR
- Argentina
- Prior art keywords
- mhc
- domain
- molecule
- stabilized
- mhc molecule
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente concierne a un método para el cribado ultrarrápido para identificar un complejo que se une a un TCR constituido por una molécula del MHC y un ligando peptídico, el cual comprende una molécula de MHC-péptido estabilizada y los usos respectivos de dicho método. La presente concierne, además, a polipéptidos que comprenden o consisten en moléculas MHC estabilizadas o en fragmentos de unión a péptidos de las mismas, a composiciones farmacéuticas que comprenden dichos polipéptidos, vacunas que comprenden dicha composición farmacéutica y usos de dicha vacuna para la fabricación de un medicamento y/o para la prevención del cáncer. La presente concierne, además, a ácidos nucleicos que codifican dichos polipéptidos y a vectores que comprenden dichos ácidos nucleicos. Reivindicación 1: Método para el cribado de un complejo que se une a un TCR formado por una molécula del MHC y un ligando peptídico (pMHC), que comprende las etapas siguientes: a) proporcionar una molécula del MHC convenientemente estabilizada, en que dicha molécula del MHC comprende al menos un puente covalente artificialmente introducido: (I) entre un aminoácido del dominio a-1 y un aminoácido del dominio a-2 de dicha molécula del MHC estabilizada en el caso del MHC I; y/o (II) entre dos aminoácidos del dominio a-1 de dicha molécula del MHC estabilizada en el caso del MHC I; o (III) entre dos aminoácidos del dominio a-1 o del dominio b-1 de dicha molécula del MHC estabilizada en el caso del MHC II; y/o (IV) entre un aminoácido del dominio a-1 y un aminoácido del dominio b-1 de dicha molécula del MHC estabilizada en el caso del MHC II; b) la puesta en contacto de dicha molécula del MHC convenientemente estabilizada con una multitud de ligandos peptídicos de la misma, para formar complejos de molécula MHC / ligando peptídico (pMHC), y c) cribado de dichos complejos moleculares pMHC según su unión a TCR.This is concerned with a method for ultra-rapid screening to identify a complex that binds to a TCR consisting of an MHC molecule and a peptide ligand, which comprises a stabilized MHC-peptide molecule and the respective uses of said method. The present also concerns polypeptides comprising or consisting of stabilized MHC molecules or peptide-binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacture of a drug and / or for the prevention of cancer. The present also concerns nucleic acids encoding said polypeptides and vectors comprising said nucleic acids. Claim 1: Method for the screening of a complex that binds to a TCR formed by an MHC molecule and a peptide ligand (pMHC), comprising the following steps: a) providing a suitably stabilized MHC molecule, in which said molecule MHC comprises at least one artificially introduced covalent bridge: (I) between an amino acid of the a-1 domain and an amino acid of the a-2 domain of said stabilized MHC molecule in the case of MHC I; and / or (II) between two amino acids of the a-1 domain of said stabilized MHC molecule in the case of MHC I; or (III) between two amino acids of the a-1 domain or of the b-1 domain of said stabilized MHC molecule in the case of MHC II; and / or (IV) between one amino acid of domain a-1 and one amino acid of domain b-1 of said stabilized MHC molecule in the case of MHC II; b) contacting said suitably stabilized MHC molecule with a multitude of peptide ligands thereof, to form MHC molecule / peptide ligand (pMHC) complexes, and c) screening of said pMHC molecular complexes according to their binding to TCR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731337P | 2018-09-14 | 2018-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114735A1 true AR114735A1 (en) | 2020-10-07 |
Family
ID=73042390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102633A AR114735A1 (en) | 2018-09-14 | 2019-09-13 | METHOD FOR ULTRA-RAPID AFFINITY SCREENING OF MHC-PEPTIDE COMPLEXES IN SEARCH OF TCR LIGANDS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR114735A1 (en) |
-
2019
- 2019-09-13 AR ARP190102633A patent/AR114735A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210746A1 (en) | METHOD FOR ULTRA-RAPID AFFINITY SCREENING OF MHC-PEPTIDO COMPLEXES IN SEARCH OF TCR LIGANDS | |
| CY1122195T1 (en) | SERPIN FUSION POLYPEPTIDES AND METHODS OF USING THEM | |
| BR112018073289A2 (en) | binding molecules, isolated polynucleotide, vector, host cell, methods for producing the binding molecule, for treating an individual with cancer and for positively regulating or prolonging t-cell activity, pharmaceutical composition and use of the binding molecule | |
| BR112017009006A2 (en) | binding molecule, isolated polynucleotide, vector, host cell, binding molecule production method, pharmaceutical composition, use of the binding molecule, and method of treating a disease in an individual | |
| BR112018072485A2 (en) | bispecific binding proteins and uses thereof | |
| CY1122175T1 (en) | STRUCTURES OF POLYSPECIFIC ANTIBODY | |
| CY1123419T1 (en) | HIGH AFFINITY SIRP-ALPHA REAGENTS | |
| CR20190426A (en) | IMMUNOCONJUGATES | |
| EA201891127A1 (en) | Nucleic acid sequences encoding the amino acid sequence REPEATED WITH A HIGH CONTENT proline and alanine residue, having a nucleotide sequence with a low repeatability | |
| CY1117162T1 (en) | METHOD OF CONSTRUCTION OF FC-CATHERMAL PARTICULAR PARTS USING ELECTROSTATIC GUIDELINES | |
| AR105444A1 (en) | THERAPEUTIC ANTIBODIES THAT JOIN THE PROTEIN CODIFIED BY THE GENOPHYPE ACTIVATION GEN 3 (LAG3) | |
| PE20142451A1 (en) | COMPOSITIONS OF CONJUGATES OF XTEN AND METHODS TO MAKE THEM | |
| BR112017020986A2 (en) | recombinant binding proteins and their use | |
| BR112016014913A8 (en) | antibody, or an antigen-binding fragment thereof, conjugate, nucleic acid, vector, host cell, pharmaceutical composition, method of preparing an antibody light chain or antigen-binding fragment, and method of preparing a conjugate | |
| UY35854A (en) | METHODS FOR THE CONJUGATION OF OXIMA WITH KEY-MODIFIED POLYPEPTIDES | |
| BR112018007960A2 (en) | conjugate, pcrv protein, immunogenic composition, methods of preparing an immunogenic composition, treating and producing a bioconjugate, polynucleotide, vector, host cell, and, bioconjugate. | |
| CY1110848T1 (en) | NOGO HUMAN ANTI-ANTIQUE AND THE PHARMACEUTICAL OF THE USE | |
| BR112015008036A2 (en) | isolated peptide population, method for detecting antibody in a sample, method for diagnosing monocytic and / or granulocytic erlichiosis, and kit | |
| CO2020000369A2 (en) | Polypeptides that bind to the complement component c5 or serum albumin and their fusion proteins | |
| EA202191651A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC TO MT1-MMP | |
| AR114735A1 (en) | METHOD FOR ULTRA-RAPID AFFINITY SCREENING OF MHC-PEPTIDE COMPLEXES IN SEARCH OF TCR LIGANDS | |
| CO2021003286A2 (en) | Method for ultra-rapid affinity screening of mhc-peptide complexes for tcr ligands | |
| CL2021000621A1 (en) | Method for ultra-rapid affinity screening of mhc-peptide complexes for tcr ligands | |
| BR112018011259A2 (en) | factor viii, pharmaceutical composition, and method for treating a hemorrhagic defect in a mammal. | |
| Redeker et al. | A region within the C‐terminal domain of Ure2p is shown to interact with the molecular chaperone Ssa1p by the use of cross‐linkers and mass spectrometry |